Latest News for RNLXY
Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and - for the first time - measurable reduction in individual patient risk trajectories over 24 months NEW YORK, June 30, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, today…
Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) climbed 24% to 2.35p after the precision diagnostics company published two-year data showing its kidney disease test was linked to lasting improvements in patient health. The study of 2,470 patients with type 2 diabetes and early-stage chronic kidney disease was carried out across two US health systems, Mount Sinai in New York and Wake Forest/Atrium Health in…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RNLXY.
Senate Trading
No Senate trades found for RNLXY.
U.S. House Trading
No House trades found for RNLXY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.